Copyright © 1997 by the European Society of Cardiology.
© 1997 The European Society of Cardiology
Compliance and adverse event withdrawal
their impact on the West of Scotland Coronary Prevention Study
The West of Scotland Coronary Prevention Study Grouprevised 10 March 1997; accepted 14 March 1997.
Correspondence: Professor Ian Ford, Robertson Centre for Biostatistics, Boyd Orr Building, University of Glasgow, Glasgow G12 8QQ, U.K.
Abstract
AIMS: To assess the additional benefit gained from high compliance in the West of Scotland Coronary Prevention Study and to examine cases where withdrawal from trial medication was due to an adverse event.
METHODS: The incidence of definite coronary heart disease or non-fatal myocardial infarction, cardiovascular mortality, definite or suspect coronary heart disease death or non-fatal myocardial infarction, the need for coronary revascularization procedures, all-cause mortality and incident cancers were measured in the entire cohort and compared with the high compliance group. The adverse events associated with withdrawal were coded by body system.
RESULTS: In subjects with compliance 
75%, treatment with pravastatin resulted in a 38% risk reduction for definite coronary heart disease death or non-fatal myocardial infarction and for cardiovascular mortality, a 46% reduction in risk or coronary revascularization and a 32% risk reduction (P=0·015) for all-cause mortality.
CONCLUSION: The analysis of the effect of pravastatin in the subgroup of high compliers to randomized medication demonstrated a substantial increase in the estimated risk reductions in comparison with that achieved in the intention-to-treat analysis. This result has significant implications for the motivation of high compliance among patients and for the assessment of the cost-effectiveness of treatment.
Key Words: Primary prevention • compliance • withdrawals • on-treatment analysis • coronary heart disease • all cause mortality • pravastatin
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. B Farris and B. B. Phillips Instruments Assessing Capacity to Manage Medications Ann. Pharmacother., July 1, 2008; 42(7): 1026 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J.A. Penning-van Beest, F. Termorshuizen, W. G. Goettsch, O. H. Klungel, J. J.P. Kastelein, and R. M.C. Herings Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study Eur. Heart J., January 2, 2007; 28(2): 154 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I Gemmell, R F Heller, K Payne, R Edwards, M Roland, and P Durrington Potential population impact of the UK government strategy for reducing the burden of coronary heart disease in England: comparing primary and secondary prevention strategies. Qual. Saf. Health Care, October 1, 2006; 15(5): 339 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. S. Benner, M. F. Pollack, T. W. Smith, M. F. Bullano, V. J. Willey, and S. A. Williams Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy Am. J. Health Syst. Pharm., July 15, 2005; 62(14): 1468 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. R. Cheng, K.-s. Woo, J. C. N. Chan, B. Tomlinson, and J. H. S. You Assessing adherence to statin therapy using patient report, pill count, and an electronic monitoring device Am. J. Health Syst. Pharm., February 15, 2005; 62(4): 411 - 415. [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Jackevicius, M. Mamdani, and J. V. Tu Adherence With Statin Therapy in Elderly Patients With and Without Acute Coronary Syndromes JAMA, July 24, 2002; 288(4): 462 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. LaRosa and J. C. LaRosa Enhancing Drug Compliance in Lipid-Lowering Treatment Arch Fam Med, November 1, 2000; 9(10): 1169 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.J. Wheatley Cardiothoracic surgery in Europe: politics, pressures and practice Eur. J. Cardiothorac. Surg., December 1, 1999; 16(6): 593 - 601. [Full Text] [PDF]
|
|
|
|
 |
|
 A. L Hersh, W. C Black, and A. N. Tosteson Estimating the population impact of an intervention: a decision-analytic approach Statistical Methods in Medical Research, August 1, 1999; 8(4): 311 - 330. [Abstract] [PDF]
|
|
|
|
 |
|
 West of Scotland Coronary Prevention Study Group The effects of pravastatin on hospital admission in hypercholesterolemic middle-aged men: West of Scotland Coronary Prevention Study J. Am. Coll. Cardiol., March 15, 1999; 33(4): 909 - 915. [Abstract] [Full Text] [PDF]
|
|